Abstract | BACKGROUND: OBJECTIVE: PATIENTS AND METHODS: RESULTS: We identified 112 eligible pimavanserin initiators and 982 comparators. Pimavanserin initiators were younger and had fewer severe comorbidities, indicators of impairment, and healthcare encounters, though they had higher Parkinson's disease medication use. The crude incidence rates [cases/100 person-years] (95% CI) for composite falls/fractures were 17.8 (7.7-35.0) for pimavanserin and 40.8 (35.0-47.4) for comparators. Matching retained 108 pimavanserin initiators and 216 comparators-all characteristics were well balanced after matching-with a matched IRR ( pimavanserin vs comparator) of 0.71 (95% CI 0.27-1.67). Sensitivity analysis IRR estimates were consistently below 1.00, with a sensitivity analysis not requiring a diagnosis of psychosis resulting in an IRR estimate of 0.55 (95% CI 0.34-0.86). CONCLUSIONS:
|
Authors | J Bradley Layton, Joan Forns, Mary Ellen Turner, Colleen Dempsey, Jennifer L Bartsch, Mary S Anthony, Heather E Danysh, Mary E Ritchey, George Demos |
Journal | Drugs - real world outcomes
(Drugs Real World Outcomes)
Vol. 9
Issue 1
Pg. 9-22
(Mar 2022)
ISSN: 2199-1154 [Print] Switzerland |
PMID | 34718963
(Publication Type: Journal Article)
|
Copyright | © 2021. The Author(s). |